PMID- 33824602
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210408
IS  - 1179-1365 (Print)
IS  - 1179-1365 (Electronic)
IS  - 1179-1365 (Linking)
VI  - 13
DP  - 2021
TI  - Potential Benefits of the Self-Administration of Subcutaneous Methotrexate with 
      Autoinjector Devices for Patients: A Review.
PG  - 81-94
LID - 10.2147/DHPS.S290771 [doi]
AB  - The role of patient adherence in improving the efficacy of any treatment is 
      widely accepted, as well as its impact in optimizing the use of healthcare 
      resources and associated costs. Adherence is particularly affected in chronic 
      conditions, such as rheumatoid arthritis (RA), requiring long-term therapies and 
      a commitment of the patient to manage his/her disease. Methotrexate (MTX) is one 
      of the mainstays of treatment for several immune-mediated inflammatory joint and 
      skin diseases, especially RA. The use of parenteral MTX, particularly when 
      administered as a subcutaneous (SC) injection, has recently raised a great 
      interest to overcome the limitations of oral MTX. For addressing this issue, new 
      optimized self-injection systems have been developed to improve the ease of use 
      of SC MTX. Increasing evidence shows how patients tend to opt for autoinjectors 
      over prefilled syringes or conventional syringes in terms of easiness of use, 
      preference and satisfaction, regardless of whether the treatment is a biologic or 
      MTX. Additionally, positive views and beliefs of patients about treatment may 
      contribute to increasing expectations of effectiveness and treatment adherence. 
      Similarly, the implementation of prefilled pens in clinical practice might be a 
      way to facilitate and simplify the self-injection of SC MTX delivery, optimizing 
      adherence and treatment outcomes as a consequence. This article aimed to review 
      the available literature data on the use of MTX autoinjectors and their impact on 
      treatment adherence and patients' perceptions.
CI  - (c) 2021 Tornero Molina et al.
FAU - Tornero Molina, Jesus
AU  - Tornero Molina J
AD  - Department of Rheumatology, Hospital de Guadalajara, Guadalajara, Spain.
FAU - Lopez Robledillo, Juan Carlos
AU  - Lopez Robledillo JC
AD  - Department of Rheumatology, Hospital del Nino Jesus, Madrid, Spain.
FAU - Casamira Ruiz, Nuria
AU  - Casamira Ruiz N
AUID- ORCID: 0000-0002-5868-0366
AD  - Medical Department, Gebro Pharma S.A, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210329
PL  - New Zealand
TA  - Drug Healthc Patient Saf
JT  - Drug, healthcare and patient safety
JID - 101544775
PMC - PMC8018568
OTO - NOTNLM
OT  - adherence
OT  - autoinjector
OT  - methotrexate
OT  - rheumatoid arthritis
COIS- J.T.M has received honoraria from Gebro Pharma and Sanofi. J.C.L.R has received 
      honoraria from Gebro Pharma. N.C.R is an employee of Gebro Pharma, Spain. The 
      authors report no other conflicts of interest in this work.
EDAT- 2021/04/08 06:00
MHDA- 2021/04/08 06:01
PMCR- 2021/03/29
CRDT- 2021/04/07 06:23
PHST- 2020/11/07 00:00 [received]
PHST- 2021/03/02 00:00 [accepted]
PHST- 2021/04/07 06:23 [entrez]
PHST- 2021/04/08 06:00 [pubmed]
PHST- 2021/04/08 06:01 [medline]
PHST- 2021/03/29 00:00 [pmc-release]
AID - 290771 [pii]
AID - 10.2147/DHPS.S290771 [doi]
PST - epublish
SO  - Drug Healthc Patient Saf. 2021 Mar 29;13:81-94. doi: 10.2147/DHPS.S290771. 
      eCollection 2021.